<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01808313</url>
  </required_header>
  <id_info>
    <org_study_id>115812</org_study_id>
    <nct_id>NCT01808313</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)</brief_title>
  <official_title>An Open Label Phase IIIb Study to Evaluate Efficacy and Safety of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open label, single-arm, non-controlled, multicentre study will determine the effect of
      ambrisentan on exercise capacity (6MWT) in Chinese subjects with PAH. The study consists of a
      screening period of 4 weeks, a 12-week primary evaluation period (PEP) and a 12-week
      dose-adjustment period (DAP). Ambrisentan 5 mg will be administered to eligible subjects for
      12 weeks (PEP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary arterial hypertension (PAH) consists of a group of progressive and incurable
      diseases of the pulmonary vasculature. These are characterised by profound vasoconstriction
      and abnormal proliferation of smooth muscle cells in the walls of the pulmonary arteries,
      which leads to a progressive increase in pulmonary vascular resistance (PVR) and sustained
      elevations in pulmonary artery pressure (PAP). A variety of drug classes have been used to
      treat PAH but no single compound has yet been shown to be effective in treating all patients
      with the disease. Three widely used treatment options are calcium channel blockers (CCBs),
      diuretics and anticoagulants but all have varying responses.There is a lack of clinical data
      on ambrisentan among the Chinese population,Ambrisentan is conditionally approved for the
      treatment of PAH in China.A clinical trial with a minimum of 100 patients in the ambrisentan
      arm was requested by SFDA.Several PAH medications have been approved in China, so a
      placebo-controlled study is not ethically appropriate while an active control non-inferiority
      design is unfeasible due to sample size requirements and inconsistency in indications.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2012</start_date>
  <completion_date type="Actual">August 15, 2014</completion_date>
  <primary_completion_date type="Actual">August 15, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in 6-minutes Walk Test (6MWT) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The 6MWT measures the distance that a participant can walk in a period of 6 minutes. Change from Baseline was calculated as the Week 12 value minus the Baseline value. Baseline 6MWT comprised of an average of the last two consecutive measurements prior to dosing that varied by not greater than 10 percent (%). If only one measurement was available, that measurement was used as the Baseline value. The last observation carried forward method was used to impute missing values.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 6MWT at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The 6MWT measures the distance that a participant can walk in a period of 6 minutes. Change from Baseline was calculated as the Week 24 value minus the Baseline value. Baseline 6MWT comprised of an average of the last two consecutive measurements prior to dosing that varied by not greater than 10%. If only one measurement was available, that measurement was used as the Baseline value. The last observation carried forward method was used to impute missing values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Change From Baseline in Their World Health Organization (WHO) Functional Classification (FC) at Weeks 12 and 24</measure>
    <time_frame>Baseline, Week 12 and Week 24</time_frame>
    <description>The WHO FC was determined by the investigator as follows: Class I- Participants with pulmonary hypertension (PH) but without resulting limitation of physical activity, II- Participants with PH resulting in slight limitation of physical activity, III- Participants with PH resulting in marked limitation of physical activity, IV- Participants with PH with inability to carry out any physical activity without symptoms. Changes from Baseline in functional class were summarized at Weeks 12 and 24. The number of participants improving by 2 classes, improving by 1 class, not changing, worsening by 1 class or worsening by 2 classes from Baseline at Weeks 12 and 24 were evaluated. The Baseline value was the last non-missing assessment value before treatment. Only participants with non-missing Baseline values and at least one non-missing post-Baseline value of the response variable were included. The last observation carried forward method was used to impute missing values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Borg Dyspnea Index (BDI) at Weeks 12 and 24</measure>
    <time_frame>Baseline, Week 12 and Week 24</time_frame>
    <description>The BDI was calculated by using a 10-point scale (0 = None, 10 = Maximum). Change from Baseline was calculated as the Week 12 and 24 values minus the Baseline values. The BDI indicates the degree of exertion, breathlessness, fatigue, or difficulty breathing after completion of the 6MWT. The lower values, 0 as the lowest, indicates no exertion, fatigue, or breathlessness felt, and 10 would be the maximum amount of exertion felt as assessed by each participant. The last observation carried forward method was used to impute missing values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the N-Terminal Pro-B-Type Natriuretic Peptide at Weeks 12 and 24</measure>
    <time_frame>Baseline, Week 12 and Week 24</time_frame>
    <description>N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) is a surrogate maker of heart failure and was measured by a central laboratory. Mean change from Baseline at Weeks 12 and 24 were calculated as the Weeks 12 and 24 values minus the Baseline values.Observed data was analyzed (no imputation technique was performed for missing data). Log transformed mean change from Baseline at Weeks 12 and 24 data are summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Event, as an Assessment of Time to Clinical Worsening of Pulmonary Arterial Hypertension (PAH) up to Week 24, Assessed as the First Occurrence of a Particular Event</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Time to clinical worsening is defined as the time from Baseline to the first occurrence of death, lung transplantation, hospitalization for PAH treatment, atrial septostomy, or Investigational product (IP) discontinuation (discon) due to change to other PAH treatment. Time to clinical worsening was measured as the number of participants who experienced these events during 12 and 24 Weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Adverse Events, Any Serious Adverse Events and Adverse Events Leading to Discontinuation</measure>
    <time_frame>From the start of study treatment up to Week 24</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, a congenital anomaly/birth defect, or important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Physical Examination Findings</measure>
    <time_frame>Baseline, Week 12 and Week 24</time_frame>
    <description>Complete physical examinations of each participant by the investigator were performed at the Screening Visit, Week 12 and Week 24 Visit/Early withdrawal visits. The physical examination included an examination of the following: general appearance, skin, head, ears, eyes, nose, throat, neck, thyroid, lymph nodes, cardiovascular system, respiratory system, abdomen, musculoskeletal system, neurological system and height. Physical examination summary results were not collected therefore there is no data to present for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Electrocardiogram (ECG) Heart Rate Values at Weeks 12 and 24</measure>
    <time_frame>Baseline, Week 12 and Week 24</time_frame>
    <description>Heart rate was measured in order to monitor vital signs by the 12-lead ECG at Baseline, Weeks 12 and 24. Change from Baseline in ECG heart rate is summarized for each post-Baseline assessment at Weeks 12 and 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last non-missing observed value before treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Interval Corrected Bazett's Formula (QTcB) Values at Weeks 12 and 24</measure>
    <time_frame>Baseline, Week 12 and Week 24</time_frame>
    <description>The ECG parameters, PR interval, QRS duration, uncorrected QT interval, QTcB were measured at Baseline, Weeks 12 and 24. Change from Baseline in ECG heart rate is summarized for each post-Baseline assessment up to Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last non-missing observed value before treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic and Diastolic Blood Pressure at the Indicated Time Points up to Week 24</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Blood pressure measurements (pre-6MWT and post-6MWT) were taken to monitor vital signs and included systolic blood pressure (SBP) and diastolic blood pressure (DBP) at the Baseline, Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in SBP and DBP were summarized for each post-Baseline assessment upto Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last non-missing observed value before treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heart Rate at the Indicated Time Points up to Week 24</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Vital sign monitoring included heart rate measurements at (pre-6MWT and post-6MWT at the Baseline visit, Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in heart rate was summarized for each post-Baseline assessment up to Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last non-missing value observed before treatment. At Baseline, Weeks 12 and 28, heart rate was recorded at the end of the 6MWT and at 1 minute (M), 2 M and 3 M, after completion of the 6MWT with the participants seated, and the time that heart rate recovered to the level of pre-6MWT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Temperature</measure>
    <time_frame>Baseline</time_frame>
    <description>Oral temperature was used to monitor vital signs and collected at the Screening visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Shift From Baseline in Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST) and Total Bilirubin (BILT) up to Week 24</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Blood samples were collected for the measurement of ALT, ALP, AST and BILT at the Baseline visit and up to Week 24. Shift from Baseline (BL) was calculated as the individual maximum of post-BL value minus the BL value. The BL value is defined as the last pre-treatment value observed. Threshold values for the liver function test results, which were considered as potential values of clinical concern, were 3 times the upper limit of normal (ULN) for ALT, AST and ALP and 2 times the ULN for BILT. Maximum liver function abnormal values of post-BL are summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count and White Blood Cell (WBC) Count at the Indicated Time Points up to Week 24</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelet count and WBC count at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelet count and WBC count values were summarized for each post-Baseline assessment until Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hemoglobin at the Indicated Time Points up to Week 24</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Blood samples were collected for the measurement of hemoglobin at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the hemoglobin count values were summarized for each post-Baseline assessment until Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematocrit at the Indicated Time Points up to Week 24</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Blood samples were collected for the measurement of hematocrit at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the hematocrit values were summarized for each post-Baseline assessment until Week 24. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value is defined as the last Pre-treatment value observed. The unit of measure is defined as the proprtion of red blood cells in blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Corpuscle Hemoglobin at the Indicated Time Points up to Week 24</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Blood samples were collected for the measurement of mean corpuscle hemoglobin at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the hemoglobin values were summarized for each post-Baseline assessment until Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Corpuscle Volume at the Indicated Time Points up to Week 24</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Blood samples were collected for the measurement of mean corpuscle volume at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the mean corpuscle volume values were summarized for each post-Baseline assessment until Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Red Blood Cell (RBC) Count at the Indicated Time Points up to Week 24</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Blood samples were collected for the measurement of RBC count at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the red blood cell count values were summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Albumin, Globulin and Total Protein at the Indicated Time Points up to Week 24</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Blood samples were collected for the measurement of albumin, globulin and total protein at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the albumin, globulin and total protein values were summarized for each post-Baseline assessment until Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatine Kinase, Gamma Glutamyl Transferase and Lactate Dehydrogenase at the Indicated Time Points up to Week 24</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Blood samples were collected for the measurement of alkaline phosphatase (ALP), alanine amino transferase (ALT), aspartate amino transferase (AST), creatine kinase (CK), gamma glutamyl transferase (GGT) and lactate dehydrogenase (LDH) at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the ALP, ALT, AST, CK, GGT and LDH values were summarized for each post-Baseline assessment until Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Direct Bilirubin, Total Bilirubin, Creatinine and Uric Acid at the Indicated Time Points up to Week 24</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Blood samples were collected for the measurement of direct bilirubin, total bilirubin, creatinine and uric acid at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the direct bilirubin, total bilirubin, creatinine and uric acid values were summarized for each post-Baseline assessment until Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Calcium, Cholesterol, Chloride, Glucose, Potassium, Magnesium, Sodium, Inorganic Phosphorus, Triglycerides and Urea/Blood Urea Nitrogen (BUN) at the Indicated Time Points up to Week 24</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Blood samples were collected for the measurement of calcium, cholesterol, chloride, glucose, potassium, magnesium, sodium, inorganic phosphorus, triglycerides and urea/Bun at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the calcium, cholesterol, chloride, glucose, potassium, magnesium, sodium, inorganic phosphorus, triglycerides and urea/BUN values were summarized for each post-Baseline assessment until Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Urinalysis Data at Baseline and Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Urine samples were collected for urinalysis at Baseline and Week 24. The Number of participants with urinalysis to negative and positives (trace, +, ++ and +++) data at Baseline and Week 24 are summarized for urine bilirubin (UBIL), urine glucose (UGLU), urine ketones (UKET), urine nitrite (UNIT), urine protein (UM) and urine urobilinogen (UUBIL) were performed with dipstick method. Other urinalysis parameters included urine pH (UpH), urine specific gravity (USG). The Baseline value is defined as the last pre-treatment value observed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Vascular Disease</condition>
  <arm_group>
    <arm_group_label>ambrisentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ambrisentan 5 mg will be administered to eligible subjects for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ambrisentan</intervention_name>
    <description>Ambrisentan 5 mg will be administered to eligible subjects for 12 weeks</description>
    <arm_group_label>ambrisentan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent prior to beginning study-related procedures.

          -  Subject must be between 18-75 years of age, inclusive, at the Screening Visit.

          -  Subjects must weight ≥40 kg at the Screening Visit.

          -  Subjects must have symptomatic or severe PAH (WHO functional class II or III) and be
             categorised as class 1 PAH (defined by the Updated Clinical Classification of
             Pulmonary Hypertension 2009), due to iPAH, congenital heart disease-congenital heart
             defects repaired greater than 1 year prior to screening (i.e., atrial septal defects,
             ventricular septal defects or patent ductus arteriosus) or CTD-related PAH (e.g.,
             limited scleroderma, diffuse scleroderma, mixed CTD, systemic lupus erythematosus or
             overlap syndrome).

        NOTE: subjects with portopulmonary hypertension and pulmonary venoocclusive disease are NOT
        eligible for the study.

          -  Subjects must have had a right heart catheterisation within 6 months prior to
             screening and meet all of the following haemodynamic criteria:

               1. Mean PAP ≥ 25 mmHg.

               2. A PVR ≥ 240 dyn/sec/cm5.

               3. A PCWP or left ventricular (LV) end-diastolic pressure of ≤ 15 mmHg.

          -  Subjects must be able to walk a distance of at least 150 m but no more than 450 m. In
             addition, the screening and baseline 6MWT test values must not vary by greater than
             10% (calculated using (baseline - screening)/screening with the result to be between
             -0.1 and 0.1).

          -  Subjects must meet both of the following pulmonary function criteria. The tests should
             have been completed no more than 24 weeks prior to the Screening Visit, if not
             performed within the previous 24 weeks, the test must be completed at Day 0:

               1. Total lung capacity (TLC) ≥ 60% of predicted normal.

               2. Forced expiratory volume in one second (FEV1) ≥ 55% of predicted normal.

          -  Subjects receiving CCBs must be on stable therapy (i.e., the dose level does not need
             to change to maintain disease control) for at least 1 month prior to the Screening
             Visit.

          -  Subjects receiving 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase
             inhibitors (i.e., statins) must be on stable therapy (i.e., the dose level does not
             need to change to maintain disease control) for at least 12 weeks prior to the
             Screening Visit.

          -  Female subjects of childbearing potential must have a negative pregnancy test at the
             Screening Visit and Day 0.

          -  Female subjects of childbearing potential who are sexually active must agree to use
             two reliable methods of contraception (as described in Appendix 3 ) from the Screening
             Visit until study completion and for at least 30 days following the last dose of IP.
             Subjects who have had a Copper T 380A intrauterine device (IUD) or LNg 20 IUD inserted
             are not required to use an additional method of contraception.

          -  Subject must agree not to participate in a clinical study involving another IP or
             device throughout this study.

        Exclusion Criteria:

          -  The subject has received PAH therapy (PDE-5 inhibitors, ERA, chronic prostanoid*)
             within 4 weeks prior to the Screening Visit.

             *Prostanoid use is classed as chronic when treatment continues for more than 7 days.

          -  The subject has received intravenous inotropes (e.g., dopamine, dobutamine) within 2
             weeks prior to the Screening Visit.

          -  The subject has previously been discontinued from ERA treatment (e.g., bosentan) due
             to safety or tolerance issues other than those associated with liver function
             abnormalities.

          -  The subject has a serum alanine aminotransferase (ALT) or aspartate aminotransferase
             (AST) value that is &gt;2 x the upper limit of normal (ULN) at the Screening Visit.

          -  The subject has serum bilirubin value that is &gt;1.5 x ULN at the Screening Visit.

          -  The subject has severe hepatic impairment (Child-Pugh class C with or without
             cirrhosis) at the Screening Visit.

          -  The subject has severe renal impairment (creatinine clearance &lt;30 mL/min) at the
             Screening Visit.

          -  The subject has clinically significant anaemia, defined as haemoglobin concentration
             &lt;10 g/dL or haematocrit &lt;30% at the Screening Visit.

          -  The subject has a laboratory result, physical examination finding, medical history
             incident or other finding, which is a contraindication for treatment with an ERA.
             Contraindications for treatment include, but are not limited to, evidence of elevated
             liver functions test or previously experiencing an event that would be defined as a
             serious AE (SAE) in a clinical trial (see Section 6.3.3.2), which was attributed to
             treatment with an ERA.

          -  The subject has severe hypotension (either diastolic blood pressure &lt;50 mmHg or
             systolic blood pressure &lt;90 mmHg).

          -  The subject has, in the opinion of the Investigator, clinically significant aortic or
             mitral valve disease, pericardial constriction, restrictive or congestive
             cardiomyopathy, life-threatening cardiac arrhythmias, significant LV dysfunction
             (defined as LV ejection fraction &lt;45%), LV outflow obstruction, symptomatic coronary
             artery disease, autonomic hypotension or fluid depletion.

          -  The subject has a history of malignancies within the past 5 years, with the exception
             of basal cell carcinoma of the skin or in situ carcinoma of the cervix.

          -  The subject has cardiovascular, liver, renal, haematological, gastrointestinal,
             immunological, endocrine, metabolic or central nervous system disease that, in the
             opinion of the Investigator, may adversely affect the safety of the subject and/or
             efficacy of the study drug or severely limit the lifespan of the subject.

          -  A female subject who is pregnant or breastfeeding.

          -  The subject has demonstrated non-compliance with previous medical regimens or is
             unable to comply with the procedures described in this protocol.

          -  The subject has a history of abusing alcohol or drugs of abuse (including
             amphetamines, methamphetamines, opiates, cannabinoids, cocaine, benzodiazepines or
             barbiturates) within 12 months prior to the Screening Visit. Use of such drugs if
             prescribed by a Doctor and used according to the prescription would not exclude a
             subject.

          -  The subject has participated in a clinical study involving another IP or device within
             4 weeks or five half-lives of an IP, whichever is longer, before the Screening Visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hunan</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Xian</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2013</study_first_submitted>
  <study_first_submitted_qc>March 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2013</study_first_posted>
  <results_first_submitted>April 2, 2015</results_first_submitted>
  <results_first_submitted_qc>April 27, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 12, 2015</results_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ambrisentan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 134 participants were enrolled and received at least one dose of study medication. 133 participants comprised the Intent-to-Treat (ITT) Population (all participants that received at least one dose of study treatment and had an efficacy assessment performed both at Baseline and after administration of the study treatment).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ambrisentan</title>
          <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met Protocol-defined Stopping Criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ambrisentan</title>
          <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="133"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.1" spread="10.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Particiopants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian-East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in 6-minutes Walk Test (6MWT) at Week 12</title>
        <description>The 6MWT measures the distance that a participant can walk in a period of 6 minutes. Change from Baseline was calculated as the Week 12 value minus the Baseline value. Baseline 6MWT comprised of an average of the last two consecutive measurements prior to dosing that varied by not greater than 10 percent (%). If only one measurement was available, that measurement was used as the Baseline value. The last observation carried forward method was used to impute missing values.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Intent-to-Treat (ITT) Population: all participants who received at least one dose of study medication and had an efficacy assessment performed both at Baseline and after administration of the study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 6-minutes Walk Test (6MWT) at Week 12</title>
          <description>The 6MWT measures the distance that a participant can walk in a period of 6 minutes. Change from Baseline was calculated as the Week 12 value minus the Baseline value. Baseline 6MWT comprised of an average of the last two consecutive measurements prior to dosing that varied by not greater than 10 percent (%). If only one measurement was available, that measurement was used as the Baseline value. The last observation carried forward method was used to impute missing values.</description>
          <population>Intent-to-Treat (ITT) Population: all participants who received at least one dose of study medication and had an efficacy assessment performed both at Baseline and after administration of the study medication</population>
          <units>Meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.59" spread="64.494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>53.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>42.53</ci_lower_limit>
            <ci_upper_limit>64.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 6MWT at Week 24</title>
        <description>The 6MWT measures the distance that a participant can walk in a period of 6 minutes. Change from Baseline was calculated as the Week 24 value minus the Baseline value. Baseline 6MWT comprised of an average of the last two consecutive measurements prior to dosing that varied by not greater than 10%. If only one measurement was available, that measurement was used as the Baseline value. The last observation carried forward method was used to impute missing values.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 6MWT at Week 24</title>
          <description>The 6MWT measures the distance that a participant can walk in a period of 6 minutes. Change from Baseline was calculated as the Week 24 value minus the Baseline value. Baseline 6MWT comprised of an average of the last two consecutive measurements prior to dosing that varied by not greater than 10%. If only one measurement was available, that measurement was used as the Baseline value. The last observation carried forward method was used to impute missing values.</description>
          <population>ITT Population.</population>
          <units>Meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.36" spread="91.173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>64.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>48.72</ci_lower_limit>
            <ci_upper_limit>80.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Change From Baseline in Their World Health Organization (WHO) Functional Classification (FC) at Weeks 12 and 24</title>
        <description>The WHO FC was determined by the investigator as follows: Class I- Participants with pulmonary hypertension (PH) but without resulting limitation of physical activity, II- Participants with PH resulting in slight limitation of physical activity, III- Participants with PH resulting in marked limitation of physical activity, IV- Participants with PH with inability to carry out any physical activity without symptoms. Changes from Baseline in functional class were summarized at Weeks 12 and 24. The number of participants improving by 2 classes, improving by 1 class, not changing, worsening by 1 class or worsening by 2 classes from Baseline at Weeks 12 and 24 were evaluated. The Baseline value was the last non-missing assessment value before treatment. Only participants with non-missing Baseline values and at least one non-missing post-Baseline value of the response variable were included. The last observation carried forward method was used to impute missing values.</description>
        <time_frame>Baseline, Week 12 and Week 24</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Change From Baseline in Their World Health Organization (WHO) Functional Classification (FC) at Weeks 12 and 24</title>
          <description>The WHO FC was determined by the investigator as follows: Class I- Participants with pulmonary hypertension (PH) but without resulting limitation of physical activity, II- Participants with PH resulting in slight limitation of physical activity, III- Participants with PH resulting in marked limitation of physical activity, IV- Participants with PH with inability to carry out any physical activity without symptoms. Changes from Baseline in functional class were summarized at Weeks 12 and 24. The number of participants improving by 2 classes, improving by 1 class, not changing, worsening by 1 class or worsening by 2 classes from Baseline at Weeks 12 and 24 were evaluated. The Baseline value was the last non-missing assessment value before treatment. Only participants with non-missing Baseline values and at least one non-missing post-Baseline value of the response variable were included. The last observation carried forward method was used to impute missing values.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved by 2 classes at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improved by 1 class at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not changing at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsened by 1 class at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsened by 2 classes at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improved by 2 classes at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improved by 1 class at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not changing at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsened by 1 class at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsened by 2 classes at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Borg Dyspnea Index (BDI) at Weeks 12 and 24</title>
        <description>The BDI was calculated by using a 10-point scale (0 = None, 10 = Maximum). Change from Baseline was calculated as the Week 12 and 24 values minus the Baseline values. The BDI indicates the degree of exertion, breathlessness, fatigue, or difficulty breathing after completion of the 6MWT. The lower values, 0 as the lowest, indicates no exertion, fatigue, or breathlessness felt, and 10 would be the maximum amount of exertion felt as assessed by each participant. The last observation carried forward method was used to impute missing values.</description>
        <time_frame>Baseline, Week 12 and Week 24</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Borg Dyspnea Index (BDI) at Weeks 12 and 24</title>
          <description>The BDI was calculated by using a 10-point scale (0 = None, 10 = Maximum). Change from Baseline was calculated as the Week 12 and 24 values minus the Baseline values. The BDI indicates the degree of exertion, breathlessness, fatigue, or difficulty breathing after completion of the 6MWT. The lower values, 0 as the lowest, indicates no exertion, fatigue, or breathlessness felt, and 10 would be the maximum amount of exertion felt as assessed by each participant. The last observation carried forward method was used to impute missing values.</description>
          <population>ITT Population.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="1.521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="1.952"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the N-Terminal Pro-B-Type Natriuretic Peptide at Weeks 12 and 24</title>
        <description>N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) is a surrogate maker of heart failure and was measured by a central laboratory. Mean change from Baseline at Weeks 12 and 24 were calculated as the Weeks 12 and 24 values minus the Baseline values.Observed data was analyzed (no imputation technique was performed for missing data). Log transformed mean change from Baseline at Weeks 12 and 24 data are summarized.</description>
        <time_frame>Baseline, Week 12 and Week 24</time_frame>
        <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by number of participants [n]=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflect everyone in the ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the N-Terminal Pro-B-Type Natriuretic Peptide at Weeks 12 and 24</title>
          <description>N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) is a surrogate maker of heart failure and was measured by a central laboratory. Mean change from Baseline at Weeks 12 and 24 were calculated as the Weeks 12 and 24 values minus the Baseline values.Observed data was analyzed (no imputation technique was performed for missing data). Log transformed mean change from Baseline at Weeks 12 and 24 data are summarized.</description>
          <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by number of participants [n]=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflect everyone in the ITT Population.</population>
          <units>log(ng/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12, n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="2.687"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="3.103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon signed-rank test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.366</ci_lower_limit>
            <ci_upper_limit>0.519</ci_upper_limit>
            <estimate_desc>Week 12</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon signed-rank test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.303</ci_lower_limit>
            <ci_upper_limit>0.453</ci_upper_limit>
            <estimate_desc>Week 24</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Event, as an Assessment of Time to Clinical Worsening of Pulmonary Arterial Hypertension (PAH) up to Week 24, Assessed as the First Occurrence of a Particular Event</title>
        <description>Time to clinical worsening is defined as the time from Baseline to the first occurrence of death, lung transplantation, hospitalization for PAH treatment, atrial septostomy, or Investigational product (IP) discontinuation (discon) due to change to other PAH treatment. Time to clinical worsening was measured as the number of participants who experienced these events during 12 and 24 Weeks.</description>
        <time_frame>Baseline up to Week 24</time_frame>
        <population>Safety Population: This population comprised of all participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Event, as an Assessment of Time to Clinical Worsening of Pulmonary Arterial Hypertension (PAH) up to Week 24, Assessed as the First Occurrence of a Particular Event</title>
          <description>Time to clinical worsening is defined as the time from Baseline to the first occurrence of death, lung transplantation, hospitalization for PAH treatment, atrial septostomy, or Investigational product (IP) discontinuation (discon) due to change to other PAH treatment. Time to clinical worsening was measured as the number of participants who experienced these events during 12 and 24 Weeks.</description>
          <population>Safety Population: This population comprised of all participants who received at least one dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung Transplant at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalization for PAH at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrial Septostomy at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IP discon (additional medication) at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung Transplant at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalization for PAH at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrial Septostomy at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IP discon (additional medication) at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Adverse Events, Any Serious Adverse Events and Adverse Events Leading to Discontinuation</title>
        <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, a congenital anomaly/birth defect, or important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition.</description>
        <time_frame>From the start of study treatment up to Week 24</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Adverse Events, Any Serious Adverse Events and Adverse Events Leading to Discontinuation</title>
          <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, a congenital anomaly/birth defect, or important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Physical Examination Findings</title>
        <description>Complete physical examinations of each participant by the investigator were performed at the Screening Visit, Week 12 and Week 24 Visit/Early withdrawal visits. The physical examination included an examination of the following: general appearance, skin, head, ears, eyes, nose, throat, neck, thyroid, lymph nodes, cardiovascular system, respiratory system, abdomen, musculoskeletal system, neurological system and height. Physical examination summary results were not collected therefore there is no data to present for this outcome measure.</description>
        <time_frame>Baseline, Week 12 and Week 24</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Physical Examination Findings</title>
          <description>Complete physical examinations of each participant by the investigator were performed at the Screening Visit, Week 12 and Week 24 Visit/Early withdrawal visits. The physical examination included an examination of the following: general appearance, skin, head, ears, eyes, nose, throat, neck, thyroid, lymph nodes, cardiovascular system, respiratory system, abdomen, musculoskeletal system, neurological system and height. Physical examination summary results were not collected therefore there is no data to present for this outcome measure.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Summary data was not compiled for this outcome measure therefore there is no data to present.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Electrocardiogram (ECG) Heart Rate Values at Weeks 12 and 24</title>
        <description>Heart rate was measured in order to monitor vital signs by the 12-lead ECG at Baseline, Weeks 12 and 24. Change from Baseline in ECG heart rate is summarized for each post-Baseline assessment at Weeks 12 and 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last non-missing observed value before treatment.</description>
        <time_frame>Baseline, Week 12 and Week 24</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Electrocardiogram (ECG) Heart Rate Values at Weeks 12 and 24</title>
          <description>Heart rate was measured in order to monitor vital signs by the 12-lead ECG at Baseline, Weeks 12 and 24. Change from Baseline in ECG heart rate is summarized for each post-Baseline assessment at Weeks 12 and 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last non-missing observed value before treatment.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12, n=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="16.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=118</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="14.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Interval Corrected Bazett's Formula (QTcB) Values at Weeks 12 and 24</title>
        <description>The ECG parameters, PR interval, QRS duration, uncorrected QT interval, QTcB were measured at Baseline, Weeks 12 and 24. Change from Baseline in ECG heart rate is summarized for each post-Baseline assessment up to Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last non-missing observed value before treatment.</description>
        <time_frame>Baseline, Week 12 and Week 24</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Interval Corrected Bazett's Formula (QTcB) Values at Weeks 12 and 24</title>
          <description>The ECG parameters, PR interval, QRS duration, uncorrected QT interval, QTcB were measured at Baseline, Weeks 12 and 24. Change from Baseline in ECG heart rate is summarized for each post-Baseline assessment up to Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last non-missing observed value before treatment.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR interval, Week 12, n=122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="16.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval, Week 24, n=117</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="14.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration, Week 12, n=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="15.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration, Week 24, n=118</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="14.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uncorrected QT Interval, Week 12, n=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="37.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uncorrected QT Interval, Week 24, n=118</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="40.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corrected QTcB interval, Week 12, n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="29.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corrected QTcB interval, Week 24, n=117</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="37.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic and Diastolic Blood Pressure at the Indicated Time Points up to Week 24</title>
        <description>Blood pressure measurements (pre-6MWT and post-6MWT) were taken to monitor vital signs and included systolic blood pressure (SBP) and diastolic blood pressure (DBP) at the Baseline, Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in SBP and DBP were summarized for each post-Baseline assessment upto Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last non-missing observed value before treatment.</description>
        <time_frame>Baseline up to Week 24</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic and Diastolic Blood Pressure at the Indicated Time Points up to Week 24</title>
          <description>Blood pressure measurements (pre-6MWT and post-6MWT) were taken to monitor vital signs and included systolic blood pressure (SBP) and diastolic blood pressure (DBP) at the Baseline, Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in SBP and DBP were summarized for each post-Baseline assessment upto Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last non-missing observed value before treatment.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Millimeters of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP; pre-6MWT; Week 4; n=131</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="11.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; post-6MWT; Week 4; n=131</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="15.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; pre-6MWT; Week 8; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="13.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; post-6MWT, Week 8; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="17.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; pre-6MWT; Week 12; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="15.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; post-6MWT; Week 12; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="18.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; pre-6MWT; Week 16; n=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="14.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; post-6MWT; Week 16; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="17.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; pre-6MWT; Week 20; n=122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="14.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; post-6MWT, Week 20; n=122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="18.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; pre-6MWT; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="15.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; post-6MWT; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="19.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; pre-6MWT; Week 4; n=131</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="9.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; post-6MWT; Week 4; n=131</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="11.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; pre-6MWT; Week 8; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="9.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; post-6MWT; Week 8; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="11.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; pre-6MWT; Week 12; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="10.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; post-6MWT; Week 12; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="12.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; pre-6MWT; Week 16; n=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="11.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; post-6MWT; Week 16; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="14.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; pre-6MWT; Week 20; n=122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="10.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; post-6MWT; Week 20; n=122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="14.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; pre-6MWT; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="12.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; post-6MWT; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="13.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Heart Rate at the Indicated Time Points up to Week 24</title>
        <description>Vital sign monitoring included heart rate measurements at (pre-6MWT and post-6MWT at the Baseline visit, Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in heart rate was summarized for each post-Baseline assessment up to Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last non-missing value observed before treatment. At Baseline, Weeks 12 and 28, heart rate was recorded at the end of the 6MWT and at 1 minute (M), 2 M and 3 M, after completion of the 6MWT with the participants seated, and the time that heart rate recovered to the level of pre-6MWT.</description>
        <time_frame>Baseline up to Week 24</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate at the Indicated Time Points up to Week 24</title>
          <description>Vital sign monitoring included heart rate measurements at (pre-6MWT and post-6MWT at the Baseline visit, Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in heart rate was summarized for each post-Baseline assessment up to Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last non-missing value observed before treatment. At Baseline, Weeks 12 and 28, heart rate was recorded at the end of the 6MWT and at 1 minute (M), 2 M and 3 M, after completion of the 6MWT with the participants seated, and the time that heart rate recovered to the level of pre-6MWT.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart Rate; pre-6MWT; Week 4; n=131</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="12.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate; post-6MWT; Week 4; n=131</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="18.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate; pre-6MWT; Week 8; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="13.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate; post-6MWT, Week 8; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="17.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate; pre-6MWT; Week 12; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="12.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate; post-6MWT; Week 12; n=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="18.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate; post-6MWT 1M; Week 12; n=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="15.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate; post-6MWT 2 M; Week 12; n=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="13.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate; post-6MWT 3 M; Week 12; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="13.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate; Recovery to Pre-6MWT; Week 12; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="12.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate; pre-6MWT; Week 16; n=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="13.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate; post-6MWT; Week 16; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="19.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate; pre-6MWT; Week 20; n=122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="12.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate; post-6MWT, Week 20; n=122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="20.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate; pre-6MWT; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="13.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate; post-6MWT; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="21.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate; post-6MWT 1 M; Week 24; n=121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="16.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate; post-6MWT 2 M; Week 24; n=121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="13.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate; post-6MWT 3 M; Week 24; n=122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="13.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate; Recovery to Pre-6MWT; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="13.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oral Temperature</title>
        <description>Oral temperature was used to monitor vital signs and collected at the Screening visit.</description>
        <time_frame>Baseline</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Oral Temperature</title>
          <description>Oral temperature was used to monitor vital signs and collected at the Screening visit.</description>
          <population>Safety Population</population>
          <units>Celsius</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" lower_limit="35" upper_limit="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Shift From Baseline in Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST) and Total Bilirubin (BILT) up to Week 24</title>
        <description>Blood samples were collected for the measurement of ALT, ALP, AST and BILT at the Baseline visit and up to Week 24. Shift from Baseline (BL) was calculated as the individual maximum of post-BL value minus the BL value. The BL value is defined as the last pre-treatment value observed. Threshold values for the liver function test results, which were considered as potential values of clinical concern, were 3 times the upper limit of normal (ULN) for ALT, AST and ALP and 2 times the ULN for BILT. Maximum liver function abnormal values of post-BL are summarized.</description>
        <time_frame>Baseline up to Week 24</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Shift From Baseline in Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST) and Total Bilirubin (BILT) up to Week 24</title>
          <description>Blood samples were collected for the measurement of ALT, ALP, AST and BILT at the Baseline visit and up to Week 24. Shift from Baseline (BL) was calculated as the individual maximum of post-BL value minus the BL value. The BL value is defined as the last pre-treatment value observed. Threshold values for the liver function test results, which were considered as potential values of clinical concern, were 3 times the upper limit of normal (ULN) for ALT, AST and ALP and 2 times the ULN for BILT. Maximum liver function abnormal values of post-BL are summarized.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT; BL &lt;=1 x ULN shift to &gt;3 x ULN post-BL;n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; &gt;1 x - &lt;3 x ULN shift to &gt;3 x ULN; n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; &lt;=1 x ULN shift to &gt;3 x ULN; n=132</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; &gt;1 x - &lt;3 x ULN shift to &gt;3 x ULN; n=132</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; &lt;=1 x ULN shift to &gt;3 x ULN; n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; &gt;1 x - &lt;3 x ULN shift to &gt;3 x ULN; n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BILT; &gt;1 x - &lt;2 x ULN shift to &gt;2 x ULN; n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BILT; &gt;1 x - &lt;3 x ULN shift to &gt;2 x ULN; n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BILT; &gt;1 x - &gt;2 x ULN shift to &gt;2 x ULN; n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count and White Blood Cell (WBC) Count at the Indicated Time Points up to Week 24</title>
        <description>Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelet count and WBC count at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelet count and WBC count values were summarized for each post-Baseline assessment until Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.</description>
        <time_frame>Baseline up to Week 24</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count and White Blood Cell (WBC) Count at the Indicated Time Points up to Week 24</title>
          <description>Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelet count and WBC count at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelet count and WBC count values were summarized for each post-Baseline assessment until Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Giga cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils; Week 4; n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.010" spread="0.0434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; Week 8; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.007" spread="0.0479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; Week12; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.009" spread="0.0438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; Week 16; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.006" spread="0.0484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; Week 20; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.002" spread="0.0366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.002" spread="0.0792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Week 4; n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0077" spread="0.0515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Week 8; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0004" spread="0.0588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Week 12; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0012" spread="0.0603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Week 16; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0126" spread="0.1466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Week 20; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0014" spread="0.0582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0014" spread="0.0854"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Week 4; n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.257" spread="0.5558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Week 8; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.201" spread="0.6116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Week 12; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.284" spread="0.5743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Week 16; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.295" spread="0.5821"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Week 20; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.378" spread="0.6600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.363" spread="0.6897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Week 4; n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.011" spread="0.1684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Week 8; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.013" spread="0.1713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Week 12; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.032" spread="0.1659"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Week 16; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.019" spread="0.1665"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Week 20; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.044" spread="0.1574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.000" spread="0.4885"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils; Week 4; n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4093" spread="1.7597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils; Week 8; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4209" spread="1.8660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils; Week 12; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5958" spread="1.8947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils; Week 16; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7201" spread="2.1282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils; Week 20; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9510" spread="2.0706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9247" spread="2.2646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count; Week 4; n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.80" spread="41.562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count; Week 8; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.00" spread="49.357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count; Week 12; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.56" spread="54.690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count; Week 16; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.04" spread="50.227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count; Week 20; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.89" spread="52.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.75" spread="45.181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC Count; Week 4; n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.689" spread="1.9433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC count; Week 8; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.642" spread="2.1480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC count; Week 12; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.925" spread="2.1708"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC Count; Week 16; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.050" spread="2.3951"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC count; Week 20; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.387" spread="2.2706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC count; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.342" spread="2.5167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hemoglobin at the Indicated Time Points up to Week 24</title>
        <description>Blood samples were collected for the measurement of hemoglobin at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the hemoglobin count values were summarized for each post-Baseline assessment until Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.</description>
        <time_frame>Baseline up to Week 24</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin at the Indicated Time Points up to Week 24</title>
          <description>Blood samples were collected for the measurement of hemoglobin at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the hemoglobin count values were summarized for each post-Baseline assessment until Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin; Week 4; n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.46" spread="11.345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; Week 8; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.80" spread="13.642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; Week12; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.29" spread="14.269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; Week 16; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.87" spread="14.245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; Week 20; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.19" spread="14.862"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.56" spread="14.724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematocrit at the Indicated Time Points up to Week 24</title>
        <description>Blood samples were collected for the measurement of hematocrit at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the hematocrit values were summarized for each post-Baseline assessment until Week 24. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value is defined as the last Pre-treatment value observed. The unit of measure is defined as the proprtion of red blood cells in blood.</description>
        <time_frame>Baseline up to Week 24</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematocrit at the Indicated Time Points up to Week 24</title>
          <description>Blood samples were collected for the measurement of hematocrit at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the hematocrit values were summarized for each post-Baseline assessment until Week 24. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value is defined as the last Pre-treatment value observed. The unit of measure is defined as the proprtion of red blood cells in blood.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Proportion of 1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit; Week 4; n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0168" spread="0.0587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; Week 8; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0209" spread="0.0412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; Week12; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0180" spread="0.0420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; Week 16; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0179" spread="0.0443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; Week 20; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0220" spread="0.0459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0176" spread="0.0422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Corpuscle Hemoglobin at the Indicated Time Points up to Week 24</title>
        <description>Blood samples were collected for the measurement of mean corpuscle hemoglobin at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the hemoglobin values were summarized for each post-Baseline assessment until Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.</description>
        <time_frame>Baseline up to Week 24</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Corpuscle Hemoglobin at the Indicated Time Points up to Week 24</title>
          <description>Blood samples were collected for the measurement of mean corpuscle hemoglobin at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the hemoglobin values were summarized for each post-Baseline assessment until Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Picogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean Corpuscle Hemoglobin; Week 4; n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.258" spread="1.4064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscle Hemoglobin; Week 8; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.405" spread="1.5405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscle Hemoglobin; Week12; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.347" spread="2.1082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscle Hemoglobin; Week 16; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.185" spread="2.0053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscle Hemoglobin; Week 20; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.019" spread="2.0040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscle Hemoglobin; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.035" spread="2.0831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Corpuscle Volume at the Indicated Time Points up to Week 24</title>
        <description>Blood samples were collected for the measurement of mean corpuscle volume at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the mean corpuscle volume values were summarized for each post-Baseline assessment until Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.</description>
        <time_frame>Baseline up to Week 24</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Corpuscle Volume at the Indicated Time Points up to Week 24</title>
          <description>Blood samples were collected for the measurement of mean corpuscle volume at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the mean corpuscle volume values were summarized for each post-Baseline assessment until Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Femtoliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean corpuscle volume; Week 4; n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.906" spread="2.8849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean corpuscle volume; Week 8; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.362" spread="3.8958"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean corpuscle volume; Week12; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.485" spread="7.4220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean corpuscle volume; Week 16; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.725" spread="6.6333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean corpuscle volume; Week 20; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.587" spread="4.7209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean corpuscle volume; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.392" spread="4.8609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Red Blood Cell (RBC) Count at the Indicated Time Points up to Week 24</title>
        <description>Blood samples were collected for the measurement of RBC count at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the red blood cell count values were summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.</description>
        <time_frame>Baseline up to Week 24</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Red Blood Cell (RBC) Count at the Indicated Time Points up to Week 24</title>
          <description>Blood samples were collected for the measurement of RBC count at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the red blood cell count values were summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Trillion cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RBC count; Week 4; n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2773" spread="0.3678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC count; Week 8; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2987" spread="0.4781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC count; Week12; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2520" spread="0.4672"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC count; Week 16; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2595" spread="0.5066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC count; Week 20; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2733" spread="0.5414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC count; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2182" spread="0.4802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Albumin, Globulin and Total Protein at the Indicated Time Points up to Week 24</title>
        <description>Blood samples were collected for the measurement of albumin, globulin and total protein at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the albumin, globulin and total protein values were summarized for each post-Baseline assessment until Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.</description>
        <time_frame>Baseline up to Week 24</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Albumin, Globulin and Total Protein at the Indicated Time Points up to Week 24</title>
          <description>Blood samples were collected for the measurement of albumin, globulin and total protein at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the albumin, globulin and total protein values were summarized for each post-Baseline assessment until Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin; Week 4; n=132</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="4.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; Week 8; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="3.717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; Week12; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="4.105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; Week 16; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="4.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; Week 20; n=121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="4.625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; Week 24; n=120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="4.390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Globulin; Week 4; n=112</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.63" spread="5.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Globulin; Week 8; n=106</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.17" spread="6.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Globulin; Week12; n=107</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.38" spread="6.456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Globulin; Week 16; n=107</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.24" spread="6.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Globulin; Week 20; n=103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.57" spread="6.126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Globulin; Week 24; n=103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.25" spread="6.251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein; Week 4; n=132</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.19" spread="9.058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein; Week 8; n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.25" spread="8.555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein; Week12; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.57" spread="8.835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein; Week 16; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.37" spread="7.854"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein; Week 20; n=122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.60" spread="10.129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein; Week 24; n=121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.91" spread="8.841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatine Kinase, Gamma Glutamyl Transferase and Lactate Dehydrogenase at the Indicated Time Points up to Week 24</title>
        <description>Blood samples were collected for the measurement of alkaline phosphatase (ALP), alanine amino transferase (ALT), aspartate amino transferase (AST), creatine kinase (CK), gamma glutamyl transferase (GGT) and lactate dehydrogenase (LDH) at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the ALP, ALT, AST, CK, GGT and LDH values were summarized for each post-Baseline assessment until Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.</description>
        <time_frame>Baseline up to Week 24</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatine Kinase, Gamma Glutamyl Transferase and Lactate Dehydrogenase at the Indicated Time Points up to Week 24</title>
          <description>Blood samples were collected for the measurement of alkaline phosphatase (ALP), alanine amino transferase (ALT), aspartate amino transferase (AST), creatine kinase (CK), gamma glutamyl transferase (GGT) and lactate dehydrogenase (LDH) at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the ALP, ALT, AST, CK, GGT and LDH values were summarized for each post-Baseline assessment until Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>International units per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALP; Week 4; n=131</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.20" spread="14.945"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; Week 8; n=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.19" spread="16.612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; Week12; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.79" spread="16.815"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; Week 16; n=122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.47" spread="18.916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; Week 20; n=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.99" spread="18.255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; Week 24; n=121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.95" spread="23.104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week 4; n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="20.479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week 8; n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.58" spread="20.411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week12; n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.69" spread="16.770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week 16; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.33" spread="16.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week 20; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.44" spread="19.143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.62" spread="15.734"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week 4; n=132</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="24.671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week 8; n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.55" spread="13.848"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week12; n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.51" spread="13.835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week 16; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.03" spread="12.710"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week 20; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.80" spread="15.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.63" spread="12.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK; Week 4; n=129</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.78" spread="35.099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK; Week 8; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.21" spread="182.414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK; Week12; n=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="105.342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK; Week 16; n=121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="100.783"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK; Week 20; n=120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.79" spread="86.528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK; Week 24; n=116</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="89.377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT; Week 4; n=131</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.67" spread="46.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT; Week 8; n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.91" spread="49.174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT; Week12; n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.82" spread="52.509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT; Week 16; n=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.98" spread="55.130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT; Week 20; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.42" spread="58.287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT; Week 24; n=122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.84" spread="56.557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDH; Week 4; n=122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.45" spread="53.720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDH; Week 8; n=118</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.24" spread="80.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDH; Week12; n=118</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.15" spread="77.867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDH; Week 16; n=117</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.37" spread="82.565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDH; Week 20; n=117</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.65" spread="81.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDH; Week 24; n=113</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.38" spread="74.551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Direct Bilirubin, Total Bilirubin, Creatinine and Uric Acid at the Indicated Time Points up to Week 24</title>
        <description>Blood samples were collected for the measurement of direct bilirubin, total bilirubin, creatinine and uric acid at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the direct bilirubin, total bilirubin, creatinine and uric acid values were summarized for each post-Baseline assessment until Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.</description>
        <time_frame>Baseline up to Week 24</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Direct Bilirubin, Total Bilirubin, Creatinine and Uric Acid at the Indicated Time Points up to Week 24</title>
          <description>Blood samples were collected for the measurement of direct bilirubin, total bilirubin, creatinine and uric acid at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the direct bilirubin, total bilirubin, creatinine and uric acid values were summarized for each post-Baseline assessment until Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Micromoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Direct Bilirubin; Week 4; n=131</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.326" spread="2.0821"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Bilirubin; Week 8; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.538" spread="2.5429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Bilirubin; Week12; n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.787" spread="2.5038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Bilirubin; Week 16; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.778" spread="2.7692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Bilirubin; Week 20; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.780" spread="2.5072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Bilirubin; Week 24; n=122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.752" spread="2.7299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin; Week 4; n=131</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="5.903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin; Week 8; n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.12" spread="6.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin; Week12; n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="17.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin; Week 16; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.49" spread="6.866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin; Week 20; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.65" spread="6.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.25" spread="6.927"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; Week 4; n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.924" spread="10.1256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; Week 8; n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.968" spread="10.7823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; Week12; n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.759" spread="9.2949"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; Week 16; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.847" spread="10.0814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; Week 20; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.970" spread="9.3502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.217" spread="9.9447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid; Week 4; n=129</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.289" spread="82.7246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid; Week 8; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.159" spread="87.0456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid; Week12; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.580" spread="83.7145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid; Week 16; n=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.149" spread="87.9857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid; Week 20; n=119</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.584" spread="94.9378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid; Week 24; n=121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.168" spread="95.0694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Calcium, Cholesterol, Chloride, Glucose, Potassium, Magnesium, Sodium, Inorganic Phosphorus, Triglycerides and Urea/Blood Urea Nitrogen (BUN) at the Indicated Time Points up to Week 24</title>
        <description>Blood samples were collected for the measurement of calcium, cholesterol, chloride, glucose, potassium, magnesium, sodium, inorganic phosphorus, triglycerides and urea/Bun at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the calcium, cholesterol, chloride, glucose, potassium, magnesium, sodium, inorganic phosphorus, triglycerides and urea/BUN values were summarized for each post-Baseline assessment until Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.</description>
        <time_frame>Baseline up to Week 24</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Calcium, Cholesterol, Chloride, Glucose, Potassium, Magnesium, Sodium, Inorganic Phosphorus, Triglycerides and Urea/Blood Urea Nitrogen (BUN) at the Indicated Time Points up to Week 24</title>
          <description>Blood samples were collected for the measurement of calcium, cholesterol, chloride, glucose, potassium, magnesium, sodium, inorganic phosphorus, triglycerides and urea/Bun at the Baseline visit and Weeks 4, 8, 12, 16, 20 and 24. Change from Baseline in the calcium, cholesterol, chloride, glucose, potassium, magnesium, sodium, inorganic phosphorus, triglycerides and urea/BUN values were summarized for each post-Baseline assessment until Week 24. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Millimoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium; Week 4; n=132</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.009" spread="0.1321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; Week 8; n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.020" spread="0.1386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; Week12; n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.008" spread="0.1340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; Week 16; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.015" spread="0.1470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; Week 20; n=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.006" spread="0.1513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.007" spread="0.1440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol; Week 4; n=132</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.034" spread="0.7416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol; Week 8; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.062" spread="0.8776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol; Week12; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.180" spread="0.9450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol; Week 16; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.281" spread="0.8570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol; Week 20; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.277" spread="0.8482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol; Week 24; n=121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.253" spread="0.8340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride; Week 4; n=131</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="7.594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride; Week 8; n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="3.858"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride; Week12; n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="3.409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride; Week 16; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="3.995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride; Week 20; n=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="3.715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="4.758"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Week 4; n=130</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.343" spread="1.7140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Week 8; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.222" spread="1.7264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Week12; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.263" spread="1.7351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Week 16; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.218" spread="1.9083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Week 20; n=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.133" spread="1.5598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Week 24; n=121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.246" spread="1.4132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Week 4; n=132</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.208" spread="0.4190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Week 8; n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.169" spread="0.4690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Week12; n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.188" spread="0.4834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Week 16; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.223" spread="0.5053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Week 20; n=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.147" spread="0.5728"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.168" spread="0.4538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium; Week 4; n=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.007" spread="0.0860"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium; Week 8; n=121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.008" spread="0.0900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium; Week12; n=119</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.008" spread="0.1032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium; Week 16; n=118</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002" spread="0.0986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium; Week 20; n=116</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.005" spread="0.0988"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium; Week 24; n=113</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.007" spread="0.0990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Week 4; n=132</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="3.196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Week 8; n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="3.270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Week12; n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="3.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Week 16; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="3.361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Week 20; n=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="3.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="4.485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorus; Week 4; n=129</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.064" spread="0.2729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorus; Week 8; n=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.085" spread="0.3164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorus; Week12; n=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.058" spread="0.4237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorus; Week 16; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.075" spread="0.3298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorus; Week 20; n=121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.091" spread="0.2792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorus; Week 24; n=120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.037" spread="0.5258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides; Week 4; n=131</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.116" spread="0.6109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides; Week 8; n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.079" spread="0.5917"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides; Week12; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.119" spread="0.7142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides; Week 16; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.124" spread="0.8533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides; Week 20; n=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.211" spread="0.6071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides; Week 24; n=122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.222" spread="0.6796"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN; Week 4; n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.438" spread="1.5434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN; Week 8; n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.527" spread="1.9777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN; Week12; n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.542" spread="1.8160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN; Week 16; n=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.655" spread="1.8838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN; Week 20; n=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.821" spread="1.8408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN; Week 24; n=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.635" spread="1.9606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Urinalysis Data at Baseline and Week 24</title>
        <description>Urine samples were collected for urinalysis at Baseline and Week 24. The Number of participants with urinalysis to negative and positives (trace, +, ++ and +++) data at Baseline and Week 24 are summarized for urine bilirubin (UBIL), urine glucose (UGLU), urine ketones (UKET), urine nitrite (UNIT), urine protein (UM) and urine urobilinogen (UUBIL) were performed with dipstick method. Other urinalysis parameters included urine pH (UpH), urine specific gravity (USG). The Baseline value is defined as the last pre-treatment value observed.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Urinalysis Data at Baseline and Week 24</title>
          <description>Urine samples were collected for urinalysis at Baseline and Week 24. The Number of participants with urinalysis to negative and positives (trace, +, ++ and +++) data at Baseline and Week 24 are summarized for urine bilirubin (UBIL), urine glucose (UGLU), urine ketones (UKET), urine nitrite (UNIT), urine protein (UM) and urine urobilinogen (UUBIL) were performed with dipstick method. Other urinalysis parameters included urine pH (UpH), urine specific gravity (USG). The Baseline value is defined as the last pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>UBIL; Baseline; negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UBIL; Baseline; positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UBIL; Week24; negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UBIL; Week 24; positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UGLU; Baseline; negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UGLU; Baseline; positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UGLU; Week24; negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UGLU; Week 24; positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UKET; Baseline; negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UKET; Baseline; positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UKET; Week24; negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UKET; Week 24; positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UNIT; Baseline; negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UNIT; Baseline; positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UNIT; Week24; negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UNIT; Week 24; positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UM; Baseline; negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UM; Baseline; positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UM; Week24; negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UM; Week 24; positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UUBIL; Baseline; negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UUBIL; Baseline; positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UUBIL; Week24; negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UUBIL; Week 24; positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>On treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of administration of the study drug (up to Week 24)</time_frame>
      <desc>SAEs and non-serious AEs were reported for members of the safety population, comprised of all participants who had received at least one dose of study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ambrisentan</title>
          <description>Participants received one tablet of 5 milligrams (mg) ambrisentan (AMB) once daily (QD) for the first 12 Weeks. After 12 Weeks, the AMB dose was titrated to either one tablet of 5 mg QD or one tablet of 10 mg QD, as determined by the investigator for another 12 Weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis glandularis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRAS">Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

